Rani Therapeutics Holdings, Inc. (RANI)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q1-2026 | 8-K (2026-05-15) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-03-26) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-06) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-07) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-13) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-03-31) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-14) · 99.1 | ||
| 10-Q | Q2-2024 | — | ||
| 10-Q | Q1-2024 | 8-K (2024-05-06) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-03-20) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-11-08) · 99.1 | 8-K (2023-11-01) · 99.1 | ||
| 10-Q | Q2-2023 | 8-K (2023-08-11) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Document and Entity Information | ||
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Operations | ||
| Consolidated Statements of Comprehensive Loss | ||
| Condensed Consolidated Statements of Changes In Stockholders' (deficit)/equity (unaudited) | — |
|
| Consolidated Statements of Changes In Stockholder's Equity | ||
| Consolidated Statements of Changes In Stockholders' Equity/convertible Preferred Units and Member's Deficit | — |
|
| Consolidated Statements of Changes In Stockholder's Equity (P) | ||
| Consolidated Statements of Cash Flows | ||
| Consolidated Statements of Cash Flows (P) | ||
| Notes | ||
| Accrued Expenses | — |
|
| Accrued Expenses and Other Current Liabilities | — |
|
| Balance Sheet Components | ||
| Cash Equivalents, Restricted Cash Equivalents and Marketable Securities | — |
|
| Cash, Cash Equivalents, Restricted Cash Equivalents and Marketable Securities | ||
| Collaborative and Evaluation Arrangements | — |
|
| Collaborative Arrangements | — |
|
| Commitments and Contingencies | ||
| Cybersecurity Risk Management, Strategy, and Governance | — |
|
| Evaluation and Collaborative Arrangements | ||
| Evaluation, Collaboration and License, and Collaborative Arrangements | — |
|
| Fair Value Measurements | ||
| Income Taxes | ||
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Leases | ||
| Long Term Debt | — |
|
| Long-term Debt | — |
|
| Nature of Business, Organization and Liquidity | — |
|
| Net Loss Per Share | ||
| Organization and Nature of Business | ||
| Pay Vs Performance Disclosure | ||
| Related Party Transactions | ||
| Segment Information | — |
|
| Stock-based Compensation | ||
| Stockholders' Equity | ||
| Subsequent Events | ||
| Summary of Significant Accounting Policies | ||
| Warrants | ||